NCT05700149 Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
| NCT ID | NCT05700149 |
| Status | Recruiting |
| Phase | — |
| Sponsor | International Extranodal Lymphoma Study Group (IELSG) |
| Condition | Nodal Marginal Zone Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-04-11 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-04-11 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
Eligibility Criteria
Inclusion Criteria: 1. Male or female adults 18 years or older 2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000 3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve 4. Availability of the baseline and follow-up annotations Exclusion Criteria: 1\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)
Contact & Investigator
Davide Rossi, MD
STUDY CHAIR
Oncology Institute of Southern Switzerland and Institute of Oncology Research
Frequently Asked Questions
Who can join the NCT05700149 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nodal Marginal Zone Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05700149 currently recruiting?
Yes, NCT05700149 is actively recruiting participants. Contact the research team at ielsg@ior.usi.ch for enrollment information.
Where is the NCT05700149 trial being conducted?
This trial is being conducted at Miami, United States, Rochester, United States, New York, United States, Columbus, United States and 11 additional locations.
Who is sponsoring the NCT05700149 clinical trial?
NCT05700149 is sponsored by International Extranodal Lymphoma Study Group (IELSG). The principal investigator is Davide Rossi, MD at Oncology Institute of Southern Switzerland and Institute of Oncology Research. The trial plans to enroll 300 participants.